Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

140 results about "Embryonic antigen" patented technology

Preparation and application of alpha fetoprotein and carcino-embryonic antigen electrochemiluminescence sensor

The invention provides preparation and application of an alpha fetoprotein and carcino-embryonic antigen electrochemiluminescence sensor, and belongs to the technical fields of nano function material, clinical analysis, a bioseneor technology and electrochemistry. The characteristics that platinum nanoparticle @meso-porous silicon @ graphene nanocomposite (PtNPs@m-Si@GS) is strong in conductivity, good in stability, large in specific surface area, good in biocompatibility, strong in catalytic activity and the like are utilized in preparation; an alpha fetoprotein second antibody (anti-alpha fetoprotein (AFP)) and a carcino-embryonic antigen secondary antibody (anti-carcino-embryonicantigen (CEA)) are marked, so as to prepare the marked second antibodies Ru-PtNPs@M-Si@GS/anti-AFP and luminol-PtNPs@M-Si@GS/anti-CEA; and the sensitivity of the sensor is obviously improved. Compared with other single-channel electrode sensors, alpha fetoprotein and carcino-embryonic antigen can be simultaneously detected on a same electrode at one time; the detection efficiency is obviously improved; and the alpha fetoprotein and carcino-embryonic antigen electrochemiluminescence sensor has important scientific significance and application value on clinical early diagnosis of hepatic carcinoma.
Owner:UNIV OF JINAN

Chimeric antigen receptor for identifying carcino-embryonic antigens and application of chimeric antigen receptor

The invention belongs to the field of gene engineering, and particularly relates to a chimeric antigen receptor for identifying carcino-embryonic antigens and an application of the chimeric antigen receptor. A single-chain fragment variable (scFV) for identifying the carcino-embryonic antigens, a hinge region, a transmembrane region and an intracellular signal domain are sequentially connected to form the chimeric antigen receptor, and the amino acid sequence of the single-chain fragment variable (scFV) for identifying the carcino-embryonic antigens includes M5A-scFV amino acid sequence or amino acid sequence acquired by performing random mutation on M5A-scFV polypeptide. When the chimeric antigen receptor identifies the carcino-embryonic antigens, T lymphocytes can be more stably expressed, the positive rate of a chimeric antigen receptor of a target CEA (carcino-embryonic antigen) can be maintained in the culture process of patient cells, proliferation capacity and tumor killing capacity of CAR-T (chimeric antigen receptor T lymphocytes) can be improved, the chimeric antigen receptor does not have toxic and side effects on confrontation of original negative cells, can be used for targeted treatment of tumors and high in humanization degree, immunogenicity of the CAR can be effectively reduced, and continuity and safety of the CAR-T in human bodies are improved.
Owner:CHONGQING PRECISION BIOTECH CO LTD

Method for auxiliary diagnosis of liver cancer by means of combined detection of tumor markers based on artificial neural network

The invention discloses a method for auxiliary diagnosis of liver cancer by means of combined detection of tumor markers based on an artificial neural network. The method comprises the following steps: collecting a blood sample of a patient; adopting a chemiluminesent immunoassay kit to respectively measure the contents of alpha fetoprotein (AFP), carcino-embryonic antigen (CEA) and carbohydrate antigen 125 (CA125) in serum; measuring the level of sialic acid (SA) in the serum by applying a visible spectrophotometry; measuring the level of Ca in the serum by using an azo arsenic III end-point method; carrying out descriptive statistical analysis on all data by using statistics, and taking diagnostic sensitivity, specificity, accuracy, a positive predictive value and a negative predictive value as evaluation indexes; adopting a back-propagation neural network algorithm to obtain a trained model; using the trained model to predict a corresponding test set. The method provided by the invention is high in accuracy rate and can be used for well distinguishing the liver cancer, benign and normal, thus having good popularization and application prospects.
Owner:中国人民解放军第一五九医院

Method for detecting carcino-embryonic antigens by using electrochemical nucleic acid aptamer sensor on basis of terminal elongases

The invention discloses a method for detecting carcino-embryonic antigens by using an electrochemical nucleic acid aptamer sensor on the basis of terminal elongases. The method comprises the following steps: modifying a layer of 3' mercapto-terminated labeled carcino-embryonic antigen aptamer capturing probes on the surface of a gold electrode at first; then adding carcino-embryonic antigens and carcino-embryonic antigen aptamer signal probes, wherein the 3' mercapto-terminated labeled carcino-embryonic antigen aptamer capturing probes and the carcino-embryonic antigen aptamer signal probes can specifically recognize the carcino-embryonic antigens, so that a sandwich structure is formed on the surface of the electrode; extending biotin labeled nucleic acid long chains at 3' terminals of the carcino-embryonic antigen aptamer signal probes under the effect of terminal deoxynucleotidyl transferase, wherein avidin labeled horse radish peroxidase can be combined to the biotin labeled nucleic acid long chains in a compatible manner; and detecting electrochemical signal change generated by horse radish peroxidase catalyzed electrolyte so as to realize high-sensitivity and high-specificity detection on the carcino-embryonic antigens. The method can be used for early diagnosis of tumors, curative effect judgment, progression of the disease, prognosis estimation and the like.
Owner:迈科若(苏州)医疗科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products